Swiss Rockets secured an exclusive license from MGI Tech and Complete Genomics for CoolMPS sequencing chemistry outside the Asia‑Pacific region, positioning the Basel‑based incubator to develop and commercialize CoolMPS‑based NGS platforms as early as next year. The deal gives Swiss Rockets perpetual rights globally except APAC and offers an option to expand into Asia‑Pacific in 2026. Swiss Rockets plans to rely on Complete Genomics and MGI manufacturing expertise to accelerate platform development, citing perceived geopolitical advantages for a Swiss‑based vendor in European and U.S. markets. Executives signaled a focus on multi‑omics applications for oncology and immunology diagnostics. The move represents a new entrant in NGS instrumentation and could intensify competition in sequencing hardware, particularly in markets sensitive to supply‑chain and geopolitical considerations.